Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh H H, Goldbach-Mansky R, Dean J, Athreya B, Reginato A J, Henrickson M, Pons-Estel B, O'Shea J J, Kastner D L
Section of Genetics, Arthritis and Rheumatism Branch, National Institutes of Health, Bethesda, MD 20892, USA.
Am J Hum Genet. 2001 Aug;69(2):301-14. doi: 10.1086/321976. Epub 2001 Jul 6.
Mutations in the extracellular domain of the 55-kD tumor-necrosis factor (TNF) receptor (TNFRSF1A), a key regulator of inflammation, define a periodic-fever syndrome, TRAPS (TNF receptor-associated periodic syndrome [MIM 142680]), which is characterized by attacks of fever, sterile peritonitis, arthralgia, myalgia, skin rash, and/or conjunctivitis; some patients also develop systemic amyloidosis. Elsewhere we have described six disease-associated TNFRSF1A mutations, five of which disrupt extracellular cysteines involved in disulfide bonds; four other mutations have subsequently been reported. Among 150 additional patients with unexplained periodic fevers, we have identified four novel TNFRSF1A mutations (H22Y, C33G, S86P, and c.193-14 G-->A), one mutation (C30S) described by another group, and two substitutions (P46L and R92Q) present in approximately 1% of control chromosomes. The increased frequency of P46L and R92Q among patients with periodic fever, as well as functional studies of TNFRSF1A, argue that these are low-penetrance mutations rather than benign polymorphisms. The c.193-14 G-->A mutation creates a splice-acceptor site upstream of exon 3, resulting in a transcript encoding four additional extracellular amino acids. T50M and c.193-14 G-->A occur at CpG hotspots, and haplotype analysis is consistent with recurrent mutations at these sites. In contrast, although R92Q also arises at a CpG motif, we identified a common founder chromosome in unrelated individuals with this substitution. Genotype-phenotype studies identified, as carriers of cysteine mutations, 13 of 14 patients with TRAPS and amyloidosis and indicated a lower penetrance of TRAPS symptoms in individuals with noncysteine mutations. In two families with dominantly inherited disease and in 90 sporadic cases that presented with a compatible clinical history, we have not identified any TNFRSF1A mutation, despite comprehensive genomic sequencing of all of the exons, therefore suggesting further genetic heterogeneity of the periodic-fever syndromes.
55kD肿瘤坏死因子(TNF)受体(TNFRSF1A)的细胞外结构域发生突变,TNFRSF1A是炎症的关键调节因子,可导致周期性发热综合征,即肿瘤坏死因子受体相关周期性综合征(TRAPS,[MIM 142680]),其特征为发热、无菌性腹膜炎、关节痛、肌痛、皮疹和/或结膜炎发作;部分患者还会发展为系统性淀粉样变性。我们在其他地方描述了6种与疾病相关的TNFRSF1A突变,其中5种破坏了参与二硫键形成的细胞外半胱氨酸;随后又报道了另外4种突变。在另外150例不明原因周期性发热患者中,我们发现了4种新的TNFRSF1A突变(H22Y、C33G、S86P和c.193-14 G→A),另一个研究小组描述的1种突变(C30S),以及在约1%的对照染色体中出现的2种替换(P46L和R92Q)。周期性发热患者中P46L和R92Q的频率增加,以及TNFRSF1A的功能研究表明,这些是低外显率突变而非良性多态性。c.193-14 G→A突变在第3外显子上游产生一个剪接受体位点,导致转录本编码另外4个细胞外氨基酸。T50M和c.193-14 G→A发生在CpG热点,单倍型分析与这些位点的反复突变一致。相比之下,虽然R92Q也出现在一个CpG基序上,但我们在具有这种替换的无关个体中发现了一条常见的始祖染色体。基因型-表型研究确定,14例TRAPS和淀粉样变性患者中有13例为半胱氨酸突变携带者,并表明非半胱氨酸突变个体中TRAPS症状的外显率较低。在两个显性遗传疾病家族和90例具有相似临床病史的散发性病例中,尽管对所有外显子进行了全面的基因组测序,我们未发现任何TNFRSF1A突变,因此提示周期性发热综合征存在进一步的遗传异质性。